MedTech Acquisition Corp

MedTech Acquisition Corp. is a blank check company, whose business purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It intends to focus on businesses primarily operating in the healthcare sector in the United States. The company was founded on September 11, 2020 and is headquartered in New York, NY. Redemption Price: 10. Warrant Coverage: 1/3.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company was founded on September 11, 2020, and is headquartered in Westminster, CO.

The Special Purpose Acquisition Company (SPAC) begins trading publicly. During this phase the SPAC looks for a target company to merge with or acquire.

PREVIOUS PHASE

The SPAC announces which company it will be acquiring (and taking public).

CURRENT PHASE

Investors and shareholders will meet to approve the acquisition.

NEXT PHASE

DENVER & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, today announced the completion of its previously announced merger with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech). TriSalus' common stock and warrants are expected to commence trading on the Nasdaq Global Market under the ticker.

TriSalus Life Sciences Completes Merger with MedTech Acquisition Corporation

NEW YORK--(BUSINESS WIRE)--MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech” or the “Company”) today announced that it convened and then adjourned, without conducting any business, its special meeting of stockholders (the “Special Meeting”). The Special Meeting is being held to vote on certain proposals related to the proposed business combination (the “Business Combination”) with TriSalus Life Sciences (“TriSalus”). The Special Meeting has been adjourned until 11:00 a.m. Eastern Time o.

MedTech Acquisition Corporation Adjourns Special Meeting of Stockholders

DENVER & CHICAGO--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (TriSalus or the Company), an oncology company in the process of going public through a business combination transaction (the Business Combination) with MedTech Acquisition Corporation (Nasdaq: MTAC) (MedTech or MTAC), today announced additional Phase 1 clinical data presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting taking place in Chicago, Illinois, from June 2-6, 2023. TriSalus' ongoing Phase 1 Pr.

TriSalus Life Sciences Presents Additional Data for SD-101 Delivered by the Proprietary PEDD™ Method with the TriNav™ Device for Uveal Melanoma Liver Metastases at the ASCO 2023 Annual Meeting

DENVER & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc., (“TriSalus” or the “Company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech” or “MTAC”), today announced new Phase 1 clinical data presented at the American Association for Cancer Research (“AACR”) 2023 Annual Meeting taking place in Orlando, Florida, from April 14-19, 2023.

TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases

DENVER & CHICAGO--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech” or “MTAC”), today announced that James “Jim” Alecxih has joined the Company in the newly created role of President, Device Technology Business. Mr.

TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

DENVER & CHICAGO--(BUSINESS WIRE)--TriSalus Life Sciences®, Inc.

TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

DENVER & CHICAGO--( BUSINESS WIRE )--TriSalus Life Sciences®, Inc. (“TriSalus” or the “company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech” or “MTAC”), today announced that it has expanded the reach of its ongoing Pressure-Enabled Regional Immuno-Oncology™ (“PERIO™-01” and “PERIO™-02”) clinical program.

TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments

The Company recommends all of its stockholders to vote FOR the Extension Amendment at the upcoming Special Meeting.

MedTech Acquisition Corporation Announces Adjournment of its Special Meeting in lieu of an Annual Meeting of Stockholders

TriSalus Life Sciences®, Inc. (“TriSalus”) (the “Company”), an oncology therapeutics company in the process of going public through a business combination transaction (the “Business Combination”) with MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech” or “MTAC”), today filed a presentation for investors with additional information regarding its ongoing Pressure-Enabled Regional Immuno-Oncology™ (“PERIO™ 01”) and (“PERIO™ 02”) clinical studies for primary and metastatic liver tumors.

TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

DENVER & FORT LAUDERDALE, Fla.--( BUSINESS WIRE )--TriSalus Life Sciences® (the “Company” or “TriSalus”), a privately held oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment paradigm for patients with liver and pancreatic tumors, today announced it has entered into a definitive merger agreement with MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech”), a publicly traded special purpose acquisition company. Upon the closing of the transaction, the combined company will be a publicly traded company and its common stock is expected to be listed on the NASDAQ Stock Exchange under the ticker “TLSI”. The transaction represents a post-transaction market capitalization of approximately $244.4 million for TriSalus upon closing.

TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation

TEL AVIV, Israel and FORT LAUDERDALE, Fla., March 10, 2022 (GLOBE NEWSWIRE) -- MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech”), a publicly traded special purpose acquisition company (SPAC) focused on medical technology, and Memic Innovative Surgery Ltd. (“Memic”), a medical device company dedicated to transforming surgery with its proprietary surgical robotic technology, today announced that both companies have mutually agreed to terminate, effective immediately, their previously announced business combination agreement dated August 12, 2021 due to market conditions and associated volatility as a result of recent world events.

MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination

TEL AVIV, Israel and FORT LAUDERDALE, Fla., Jan. 6, 2022 /PRNewswire/ -- Memic Innovative Surgery Ltd.

Memic Announces Adoption of Hominis® Surgical System at Three Leading U.S. Hospitals in Q4 2021

TEL AVIV, Israel and FORT LAUDERDALE, Fla., Sept. 9, 2021 /PRNewswire/ -- Memic Innovative Surgery Ltd.

Memic Announces Robert L. Ryan and Sandra Morgan to Join Board of Directors Upon Closing of Business Combination with MedTech Acquisition Corporation

OR YEHUDA, Israel, Aug. 19, 2021 /PRNewswire/ -- Peregrine Ventures portfolio company Memic Innovative Surgery Ltd. has entered into a definitive agreement for a business combination with MedTech Acquisition Corporation (NASDAQ: MTAC), a publicly traded special purpose acquisition company (SPAC) focused on medical technology, including surgical robots.

Peregrine Ventures Portfolio Company Memic Announces $1B Valuation SPAC deal

A SPAC led by the founder of Memic Innovative Surgery and several experienced medical device company executives has announced its merger partner.  The SPAC Deal: Memic Innovative Surgery announced a SPAC merger with MedTech Acquisition Corp (NASDAQ: MTAC) Friday.

Memic Going Public Via SPAC: What Investors Should Know About This Medical Device Company

TEL AVIV, Israel and FORT LAUDERDALE, Fla., Aug. 13, 2021 /PRNewswire/ -- Memic Innovative Surgery Ltd.

News for MedTech Acquisition Corp Stock (MTAC)